Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Pre-chemotherapy indication for Xtandi in prostate cancer

Pre-chemotherapy indication for Xtandi in prostate cancer The approval comes after a priority review for Xtandi in this pre-chemotherapy indication. ... These demonstrated that Xtandi was able to reduce the risk of death by 29% compared with placebo in the target group.

England's Cancer Drugs Fund: Naughty or NICE?

England's Cancer Drugs Fund: Naughty or NICE? Sanofi. 778. Xtandi (enzalutamide). Astellas. 656. Alimta (pemetrexed). Lilly. 573. Nexavar (sorafenib).

Exelixis axes staff as lead cancer programme fails

Exelixis axes staff as lead cancer programme fails prior treatment with docetaxel as well as Johnson &Johnson's Zytiga (abiraterone) or Astellas/Medivation's Xtandi (enzalutamide). ... already revitalised by the recent introductions of Zytiga, Xtandi and Bayer's radiopharmaceutical Xofigo (radium Ra 223

Astellas makes senior EMEA appointments

Astellas makes senior EMEA appointments Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.

NICE backs cancer drugs from Astellas and BMS

NICE backs cancer drugs from Astellas and BMS Astellas' Xtandi (enzalutamide). The National Institute for Health and Care Excellence (NICE) today backed two new cancer treatments for NHS use in England and Wales. ... These patients must also have been treated with the cytotoxic drug docetaxel and

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics